

Fig. 1. FT-IR (KBr):

1. Imatinib monomesylate Form  $\alpha$ ;
2. Imatinib monomesylate Form  $\beta$ .




Fig.2. DSC: Imatinib monomesylate Forms  $\alpha$  and  $\beta$ .




Fig. 3. XRPD: Imatinib monomesylate Form  $\alpha$ .




Fig. 4. XRPD: Imatinib monomesylate Form  $\beta$ .




Fig. 5: DSC: Imatinib dimesylate Form I.




Fig..6. DSC: Imatinib dimesylate Form II.




Fig. 7. DSC: Imatinib dimesylate, Forms I and II (~1:1).




Fig. 8. XRPD: Imatinib dimesylate Form I.




Fig. 9. XRPD: Imatinib dimesylate Form II.






Fig..10. XRPD: Imatinib dimesylate, Forms I and II (~ 1:1).




Fig. 11. FT-IR (KBr): Imatinib dimesylate Form I.




Fig. 12. FT-IR (KBr): Imatinib dimesylate Form II.




Fig. 13. FT-IR (KBr): Imatinib dimesylate, Forms I and II (~ 1:1).